Activ Surgical Announces Completion of First International Procedure Using Its ActivSight™ Intelligent Light

Rhea-AI Summary

Activ Surgical completes its first international surgery at Abdali Hospital in Jordan using its ActivSight technology, which provides enhanced visualization and real-time surgical insights. Dr. Mohamad Rassoul Abu-Nuwar, trained at the Esophageal Institute - West Penn Hospital, performed a surgical bariatric revision procedure using ActivPerfusion Mode. Hikma Ventures, a lead investor, supports the global expansion of ActivSight.

Insights

Medical Technology Analyst

The introduction of Activ Surgical's ActivSight™ Intelligent Light (ActivSight) in international markets, specifically its use in a surgical procedure in Jordan, represents a significant advancement in the field of medical technology. This device, which attaches to existing laparoscopic and robotic systems, offers enhanced visualization and real-time surgical insights without the need for dyes, which could reduce the risk of complications such as anastomotic leaks.

From an investment perspective, the successful deployment of ActivSight abroad may signal potential for market expansion and increased adoption rates, which could have a positive impact on Activ Surgical's financial performance. The backing by Hikma Ventures, through their strategic investment, not only provides capital but also validates the technology's potential in global markets, particularly in the MENA region. This could lead to a reassessment of the company's growth trajectory and market potential by investors.

Healthcare Industry Analyst

Activ Surgical's milestone in performing the first international surgery using its proprietary technology aligns with the broader trend of digital transformation in healthcare. The integration of ActivSight with standard monitors and surgical systems underscores a move towards interoperability and user-friendly innovation in medical devices. This is a critical factor in driving adoption, as it minimizes disruption to existing workflows and reduces the learning curve for medical professionals.

The capability of ActivSight to provide real-time perfusion assessment could become a differentiator in the competitive landscape of surgical devices. If long-term data supports a reduction in surgical complications, this could influence hospital purchasing decisions and insurance coverage policies, potentially creating a shift in standard surgical practices.

Global Market Analyst

Activ Surgical's expansion into international markets, particularly in developing regions such as the Middle East, indicates a strategic move to tap into emerging healthcare markets. The healthcare sector in these regions is experiencing rapid growth and modernization, presenting lucrative opportunities for medical technology companies. The partnership with Abdali Hospital and the endorsement by a leading healthcare network could serve as a catalyst for further international partnerships and sales.

Furthermore, the company's ability to secure regulatory clearances, such as the 510(k) and CE mark, is essential for market penetration and will likely play a key role in their global expansion strategy. As Activ Surgical continues to grow its international footprint, it may attract additional investment and partnerships, contributing positively to its valuation and stock market performance.

Foregut Surgeon, who trained at the Esophageal Institute - West Penn Hospital in Pennsylvania, uses Activ Surgical’s proprietary technology during surgical procedure at Abdali Hospital in Amman, Jordan

BOSTON--(BUSINESS WIRE)-- Activ Surgical, a digital surgery pioneer, announced that it has completed its first international surgery at Abdali Hospital, a member of the Clemenceau Network, in Amman, Jordan using its ActivSight™ Intelligent Light (ActivSight), which aims to provide enhanced visualization and real-time, on-demand surgical insights in the operating room. ActivSight is an easy-to-adapt module that seamlessly attaches to today’s laparoscopic and robotic systems and integrates with standard monitors. On December 24, 2023, Mohamad Rassoul Abu-Nuwar, MD, who specializes in general and advanced laparoscopic gastrointestinal surgery, foregut, as well as bariatric surgery, performed a surgical bariatric revision procedure using the ActivPerfusion™ Mode within ActivSight.

Dr. Abu-Nuwar completed a fellowship in Minimally Invasive Foregut Surgery at the AHN Esophageal Institute in Pittsburgh where he trained with Drs. Blair Jobe and Kirsten Newhams on using ActivSight in esophagectomies for cancer patients. At this program, Dr. Abu-Nuwar participated in a clinical study demonstrating that ActivSight’s Laser Speckle Contrast Imaging (LSCI) provides real-time, repeatable, and on-demand perfusion assessment without dyes to help prevent esophageal anastomotic leaks. Ahmad Abu Ghazaleh, Executive Vice Chairman of Abdali Hospital said, “We at Abdali Hospital pride ourselves in being the Middle East’s prime center for healthcare innovation and pioneering technology. The use of ActivSight by Dr. Abu-Nuwar in surgery demonstrates our commitment to patient-centered excellence.”

“West Penn was among the first hospitals where we launched ActivSight in 2022,” said Manisha Shah-Bugaj, Chief Executive Officer at Activ Surgical. “Now, with Dr. Abu-Nuwar championing our technology at Abdali Hospital and the support of one of our lead investors, Hikma Ventures (the strategic venture capital arm of Hikma Pharmaceuticals PLC), we are able to deliver intelligent information to doctors beyond the U.S. to reduce surgical complication rates. As we continue to achieve significant milestones such as this, our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make cutting-edge surgery accessible for all.”

Hikma Ventures led Activ Surgical’s Series B extension round in March 2022 and has made 20 investments to date in global digital health companies. Commenting on this milestone partnership, Lana Ghanem, Managing Director at Hikma Ventures, said, “This is the latest example of Hikma Ventures' commitment to supporting pioneering companies utilizing cutting-edge technologies to meaningfully improve patients' lives and treatment journeys and solidifies Hikma’s role in introducing new tools and solutions to patients and hospitals in the MENA region.”

Activ Surgical is transforming the operating room today through its 510(k)-cleared and CE-marked ActivSight device that seamlessly upgrades existing operating room equipment while serving as the “eyes” of their cutting-edge platform. With ActivSight, surgeons can now access critical intraoperative visual data as augmented reality overlays. To date, multiple major hospital networks across the U.S. have purchased ActivSight, and many additional customer sites are planned for 2024.

About Activ Surgical

Activ Surgical is the pioneering digital surgery company that completed the world’s first autonomous robotic surgery of soft tissue in 2018. The company aims to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all, and for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Activ Surgical is privately held, and backed by Cota Capital, BAM Funds, Hikma Ventures, Mint Ventures, Castor Ventures, Dream One Vision, NVIDIA, DNS Capital, GreatPoint Ventures (GPV), Artis Ventures, Tao Capital Partners, LRVHealth, Rising Tide VC, SONY Innovation Fund, 8VC, Fiscus Ventures, Peak 6 and Reimagined Ventures. Learn more at activsurgical.com and follow us on LinkedIn and X (formerly Twitter).

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

About Hikma Ventures

Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company. For more information, please visit www.hikmaventures.com.

About Abdali Hospital

Abdali Hospital is a 200-bed multi-specialty hospital with the mission to provide best practice patient-centered care and promote research and education. Abdali Hospital was founded by the investment group behind the Clemenceau Medical Center in Beirut, affiliated with Johns Hopkins Medicine International. Our goal is to improve the health of the community locally and internationally, by setting a new standard of excellence in medicine, providing inclusive medical care to prevent, diagnose, manage and treat health problems. For more information, please visit https://www.abdalihospital.com/ .

View source version on businesswire.com: https://www.businesswire.com/news/home/20240122908624/en/

Michael Sullivan

msullivan@spectrumscience.com

503-799-7520

Source: Activ Surgical

FAQ

What technology did Activ Surgical use in the surgery at Abdali Hospital in Jordan?

Activ Surgical used its ActivSight technology in the surgery at Abdali Hospital in Jordan.

Who performed the surgical bariatric revision procedure using ActivPerfusion Mode?

Dr. Mohamad Rassoul Abu-Nuwar performed the surgical bariatric revision procedure using ActivPerfusion Mode.

Who is the lead investor supporting the global expansion of ActivSight?

Hikma Ventures, the strategic venture capital arm of Hikma Pharmaceuticals PLC, is the lead investor supporting the global expansion of ActivSight.

What is the purpose of ActivSight technology?

ActivSight technology provides enhanced visualization and real-time surgical insights in the operating room.

Where was Dr. Mohamad Rassoul Abu-Nuwar trained?

Dr. Mohamad Rassoul Abu-Nuwar was trained at the Esophageal Institute - West Penn Hospital in Pennsylvania.

What is the significance of the surgical milestone at Abdali Hospital?

The surgical milestone at Abdali Hospital demonstrates the global expansion of ActivSight technology beyond the U.S.

What is the role of Hikma Ventures in supporting pioneering companies?

Hikma Ventures supports pioneering companies utilizing cutting-edge technologies to improve patients' lives and treatment journeys.